Company Overview
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.13.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +48.79% |
| 6 Months: | +58.58% |
| 3 Months: | +21.46% |
| 1 Month: | +7.75% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)49.98 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AVBP ArriVent BioPharma, Inc. R2K | 32.54 | -9.63 | $1.52B | 0.00% | -57.79% | -55.17% | - | - |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | 66.77M | 33.62M | 38.32M | 38.82M | 46.11M |
| Operating Income | -12.17M | -22.58M | -16.72M | -20.67M | -25.70M | - | -66.77M | -33.62M | -38.32M | -38.82M | -46.11M |
| EBITDA | - | - | - | - | - | - | -66.77M | -33.62M | -38.32M | -38.82M | -46.11M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | -64.39M | -31.40M | -34.98M | -35.54M | -43.32M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -12.17M | -21.57M | -14.40M | -17.42M | -21.87M | - | -64.39M | -31.40M | -34.98M | -35.54M | -43.32M |
| Diluted EPS | -9.45 | -10.79 | -5.52 | -0.70 | -0.65 | -0.61 | -1.90 | -0.90 | -0.83 | - | -0.96 |
| R&D Expense | 10.24M | 20.36M | 14.28M | 16.98M | 21.78M | 20.09M | 61.29M | 27.72M | 32.17M | - | 37.62M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 36.91M | 74.59M | 94.31M | 177.53M |
| Operating Income | -36.91M | -74.59M | -94.31M | -177.53M |
| EBITDA | -36.91M | -74.59M | -94.31M | -177.53M |
| Interest Expense | - | - | - | - |
| Pretax Income | -36.91M | -69.33M | -80.49M | -166.31M |
| Tax Provision | - | - | - | - |
| Net Income | -36.91M | -69.33M | -80.49M | -166.31M |
| Diluted EPS | -1.15 | -2.17 | -2.56 | -4.32 |
| R&D Expense | - | 64.88M | 79.00M | 153.35M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 182.83M | 163.10M | 274.94M | 333.17M |
| Current Assets | - | 182.62M | 159.97M | 226.98M | 332.90M |
| Cash & Equivalents | - | 163.37M | 150.39M | 74.29M | 45.54M |
| Inventory | - | - | - | - | - |
| Receivables | - | 500.00K | 761.00K | 500.00K | 60.00K |
| Total Liabilities | - | 267.94M | 316.29M | 17.29M | 25.95M |
| Current Liabilities | - | 8.36M | 11.62M | 17.27M | 25.95M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 139.00K | 317.00K | 176.00K | 14.00K |
| Total Equity | - | -85.11M | -153.19M | 257.65M | 307.22M |
| Shares Outstanding | - | 31.96M | 31.96M | 33.71M | 42.45M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -43.63M | -55.84M | -70.21M | -160.59M |
| Investing Cash Flow | 0 | 0 | -192.47M | -71.23M |
| Financing Cash Flow | 169.72M | 42.86M | 186.58M | 203.06M |
| Capital Expenditure | - | - | - | - |
| Free Cash Flow | -43.63M | -55.84M | -70.21M | -160.59M |
| Net Change in Cash | 126.09M | -12.98M | -76.10M | -28.75M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | - | - |
| Net Margin % | - | - | - | - |
| ROE % | 43.4% | 45.3% | -31.2% | -54.1% |
| ROCE % | -21.2% | -49.2% | -36.6% | -57.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Suvretta Capital Management, LLC | 9.45% | 4.40M | $152.85M |
| 2 | Infinitum Asset Management, LLC | 8.91% | 4.15M | $144.09M |
| 3 | HHLR Advisors, LTD | 8.44% | 3.93M | $136.46M |
| 4 | Orbimed Advisors LLC. | 6.50% | 3.03M | $105.14M |
| 5 | FMR, LLC | 6.48% | 3.02M | $104.75M |
| 6 | Blackrock Inc. | 5.43% | 2.53M | $87.88M |
| 7 | Octagon Capital Advisors LP | 4.23% | 1.97M | $68.45M |
| 8 | Novo Holdings A/S | 4.17% | 1.94M | $67.45M |
| 9 | Sofinnova Investments, Inc. | 3.64% | 1.70M | $58.93M |
| 10 | Vanguard Capital Management LLC | 3.28% | 1.53M | $53.10M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AVBP
EGFR Inhibitors Market to Witness Upsurge in Growth at a CAGR of 7.9% During the Forecast Period (2026-2036) Owing to the Entry of Next-generation TKIs, ADCs, and Combination Strategies with Immunotherapy| DelveInsight
DelveInsight's EGFR Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indicati…
The Evolving EGFR NSCLC Market: 8 Emerging Late-stage Therapies to Watch | DelveInsight
Non-small cell lung cancer is increasingly evolving into a biomarker-driven market, with EGFR-mutated disease emerging as one of the most commercially significant segments. The space is dominated by blockbuster EGFR-targeted therapies such …
ArriVent BioPharma Reports First Quarter 2026 Financial Results
Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026IND clearance of ARR-002, ArriVent’s dual-targeting MUC16/NaPi2b tetravalent ADC, advances into the clinic and plans to…
A Look At ArriVent BioPharma (AVBP) Valuation After FDA Clears ARR-002 Oncology Candidate
ArriVent BioPharma (AVBP) stock is in focus after the FDA cleared its investigational new drug application for ARR-002, a dual-target antibody drug conjugate for ovarian and endometrial cancers. See our latest analysis for ArriVent BioPharm…
ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers
Superior efficacy and favorable tolerability in animal models support the potential of ARR-002 to overcome limitations of single-target approachesPhase 1 initiation expected in the second half of 2026 NEWTOWN SQUARE, Pa., May 07, 2026 (GLOB…
Are You Looking for a Top Momentum Pick? Why ArriVent BioPharma, Inc. (AVBP) is a Great Choice
Does ArriVent BioPharma, Inc. (AVBP) have what it takes to be a top stock pick for momentum investors? Let's find out.
AVBP — Frequently Asked Questions
What is the current share price of ArriVent BioPharma, Inc. (AVBP)?
As of 2026-07-14 21:23 PDT, ArriVent BioPharma, Inc. (AVBP) trades at $32.54 on NasdaqGM. Its 52-week range is $16.95 to $34.74.
What is the market capitalisation of AVBP?
ArriVent BioPharma, Inc. (AVBP) has a market capitalisation of $1.52B on NasdaqGM.
What is the P/E ratio of AVBP?
AVBP trades at a trailing price-to-earnings (P/E) ratio of -9.63. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 4.27.
What is the return on equity (ROE) of AVBP?
AVBP has a return on equity (ROE) of -55.17%. Its return on capital employed (ROCE) is -57.79%.
Is AVBP a good stock to buy?
This page provides a data-driven analysis of ArriVent BioPharma, Inc. (AVBP), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.